Media release dated May 05, 2025, titled "Senores Pharmaceuticals acquires ANDA for Topiramate HCl 25,50,100…
As filed · Senores Pharmaceuticals Limited has informed the Exchange regarding a media release dated May 05, 2025, titled "Senores Pharmaceuticals acquires ANDA for Topiramate HCl 25,50,100 and 200 mg tablets".
What happened
FactSenores Pharmaceuticals Limited has acquired an Abbreviated New Drug Application (ANDA) for Topiramate HCl in dosages of 25, 50, 100, and 200 mg tablets. A media release regarding this acquisition has been issued and is available on the company's website. The filing is made in accordance with the Securities and Exchange Board of India regulations.
Why it matters
CapitSignal interpretationAn acquisition spends cash or issues shares today for earnings that arrive later, so the price paid and the funding route decide whether holders gain.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Margins
RevisedEBITDA margins stood at almost 30%, improving by 810 bps Y-o-Y.
Consolidated EBITDA for Q1 of FY27 stood at INR54 crores, growing by a robust 87% on a Y-o-Y basis.
Change
FactImplication
CapitSignal interpretationMargins
RevisedYes, around 100%.
But sustainable margin, what we see, gross margin, EBITDA margin for the US business is around 40%.
Change
FactImplication
CapitSignal interpretationCapex
WithdrawnOf the 35 ANDAs planned for commercialization over the next 18 to 20 months, we have already completed key building blocks required for successful execution.
The facility will not only enhance our manufacturing capacity but also enable us to enter additional regulated markets such as UK, and Canada (in addition to the US), where we currently have limited presence.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Consideration and how it is funded
- Revenue and profit of the target
- Expected completion date
- Based on the current business outlook and execution visibility, we expect the revenue growth of approximately (management committed by FY27)
- FY’27. So, next year, FY’27, we feel that margin when we get to about 18%, 20% to 22% kind of a number should (management committed by FY27)
Evidence
- Senores Pharmaceuticals Limited has informed the Exchange regarding a media release dated May 05, 2025, titled "Senores Pharmaceuticals acquires ANDA for Topiramate HCl 25,50,100 and 200 mg tablets".(opens the original filing in a new tab)
- Earlier statement · Q1 FY27
- Latest statement · Q1 FY27
- Earlier statement · Q4 FY25
- Latest statement · Q3 FY26
- Earlier statement · Q1 FY27
- Latest statement · FY27
How CapitSignal classified this
- Reasoning:
- ACQUISITION base 74; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%